| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants IMpact-RSV Study Group Pediatrics 102 (3), 531-537, 1998 | 2074 | 1998 |
| Real-time, portable genome sequencing for Ebola surveillance J Quick, NJ Loman, S Duraffour, JT Simpson, E Severi, L Cowley, JA Bore, ... Nature 530 (7589), 228-232, 2016 | 1501 | 2016 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 922 | 2022 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 741 | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 296 | 2021 |
| T-cell activation is an immune correlate of risk in BCG vaccinated infants HA Fletcher, MA Snowden, B Landry, W Rida, I Satti, SA Harris, ... Nature communications 7 (1), 11290, 2016 | 295 | 2016 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 151 | 2021 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 148 | 2021 |
| Acinetobacter in modern warfare MK O'shea International journal of antimicrobial agents 39 (5), 363-375, 2012 | 101 | 2012 |
| Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK AB Docherty, RH Mulholland, NI Lone, CP Cheyne, D De Angelis, ... The Lancet Respiratory Medicine 9 (7), 773-785, 2021 | 98 | 2021 |
| A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime–MVA85A boost in healthy UK adults M Wilkie, I Satti, A Minhinnick, S Harris, M Riste, RL Ramon, S Sheehan, ... Vaccine 38 (4), 779-789, 2020 | 90 | 2020 |
| Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study TM Drake, CJ Fairfield, R Pius, SR Knight, L Norman, M Girvan, ... The Lancet Rheumatology 3 (7), e498-e506, 2021 | 87 | 2021 |
| Sensitive detection of SARS-CoV-2–specific antibodies in dried blood spot samples GL Morley, S Taylor, S Jossi, M Perez-Toledo, SE Faustini, ... Emerging infectious diseases 26 (12), 2970, 2020 | 82 | 2020 |
| Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment MK O'Shea, MAK Ryan, AW Hawksworth, BJ Alsip, GC Gray Clinical infectious diseases 41 (3), 311-317, 2005 | 82 | 2005 |
| Distinct transcriptional and anti-mycobacterial profiles of peripheral blood monocytes dependent on the ratio of monocytes: lymphocytes V Naranbhai, HA Fletcher, R Tanner, MK O'Shea, H McShane, BP Fairfax, ... EBioMedicine 2 (11), 1619-1626, 2015 | 81 | 2015 |
| Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing TJ Wells, D Whitters, YR Sevastsyanovich, JN Heath, J Pravin, M Goodall, ... Journal of Experimental Medicine 211 (9), 1893-1904, 2014 | 79 | 2014 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 72 | 2023 |
| In vitro mycobacterial growth inhibition assays: a tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy R Tanner, MK O’Shea, HA Fletcher, H McShane Vaccine 34 (39), 4656-4665, 2016 | 72 | 2016 |
| Cytomegalovirus infection is a risk factor for tuberculosis disease in infants J Müller, R Tanner, M Matsumiya, MA Snowden, B Landry, I Satti, ... JCI insight 4 (23), 2019 | 68 | 2019 |
| The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 63 | 2021 |
